Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hypocomplementemia in multiple myeloma.

G Lugassy1, I Platok, M Schlesinger

  • 1Institute of Hematology, Barzilai Medical Center, Ashkelon, Israel.

Leukemia & Lymphoma
|April 30, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Late Relapse in Hodgkin's Disease: Report of Five Cases and a Review of the Literature.

Leukemia & lymphoma·2016
Same author

Expression of CD11a (LFA-1) on B-chronic Lymphocytic Leukemia and Lymphoma Cells: Correlation with Cell Surface Immunoglobulin Intensity and CD58 (LFA-3) Expression.

Leukemia & lymphoma·2016
Same author

Chronic Lymphocytic Leukemia in Young Adults: Report of Six Cases Under the Age of 30 Years.

Leukemia & lymphoma·2016
Same author

Hodgkin's Lymphoma: Results of ABVD Chemotherapy in 40 Patients with Advanced or Bulky Disease.

Leukemia & lymphoma·2016
Same author

Splenic Rupture in Chronic Lymphoid Disorders: Possible Role of Opportunistic Infections.

Leukemia & lymphoma·2016
Same author

MRI contrast agent concentration and tumor interstitial fluid pressure.

Journal of theoretical biology·2016
Same journal

CPX‑351 vs. FLAG‑ida in patients with high-risk AML/MDS and MDS-related gene mutations: a subgroup analysis of the UK NCRI AML19 trial.

Leukemia & lymphoma·2026
Same journal

Specialist palliative care access and end-of-life hospitalizations in acute leukemia: a nationwide register study.

Leukemia & lymphoma·2026
Same journal

D-VRD vs. D-KRD induction in transplant-eligible multiple myeloma: a real-world comparison.

Leukemia & lymphoma·2026
Same journal

T-box factor EOMES is part of an aberrant network in Hodgkin lymphoma.

Leukemia & lymphoma·2026
Same journal

Overall survival of patients with chronic lymphocytic leukemia treated with venetoclax-obinutuzumab compared to age- and sex-matched general population.

Leukemia & lymphoma·2026
Same journal

Hypertension and time to treatment failure with acalabrutinib and ibrutinib in treatment-naïve CLL/SLL.

Leukemia & lymphoma·2026
See all related articles

Multiple myeloma patients show complement system deficiencies, particularly in the common pathway. While activation occurs, no direct link was found between complement levels and disease stage or infections.

Area of Science:

  • Immunology
  • Hematology
  • Oncology

Background:

  • The complement system is crucial for immune response.
  • Multiple myeloma is a hematologic malignancy affecting plasma cells.
  • Understanding complement's role in multiple myeloma is vital for patient outcomes.

Purpose of the Study:

  • To investigate complement system pathways in multiple myeloma patients.
  • To compare complement profiles between patients and healthy controls.
  • To explore correlations between complement status, disease stage, and infections.

Main Methods:

  • Prospective study of 22 multiple myeloma patients.
  • Serum complement component levels measured for classical, alternative, and terminal pathways.
  • Comparison with 29 healthy control subjects.

Related Experiment Videos

  • Evaluation of complement pathway activation.

    • Main Results:

    • 21/22 patients exhibited a depleted common complement pathway.
    • Deficiencies in alternative and terminal pathways found in 6 patients.
    • Terminal pathway (C5-C9) activation was more frequent in advanced disease stages.
    • No correlation found between complement profile and disease stage or infectious episodes.

    Conclusions:

    • The complement system is generally deficient in multiple myeloma, likely due to systemic activation.
    • Despite deficiencies, no direct correlation was established between complement system status and clinical manifestations or infection risk.